Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Biology
Temozolomide-Nsaid Mixtures And Novel Diclofenac-Purine Hybrids As Potential Antiglioblastoma Agents, Joshua Rotich
Temozolomide-Nsaid Mixtures And Novel Diclofenac-Purine Hybrids As Potential Antiglioblastoma Agents, Joshua Rotich
Master's Theses
Glioblastoma (GBM) is the most common, lethal and aggressive brain tumor in adults. Standard treatment involves surgery, radiation therapy and temozolomide (TMZ) chemotherapy. However, GBM recurs and the average survival rate is between 12 to 18 months with 25% 1-year survival rate and 9% 5 years survival rate. Treatment options and advancement is limited by the blood brain barrier (BBB) which restricts drug entry into the brain and the immense heterogeneity of the tumor which limit adequate control of the entire tumor using one drug. In this research, we explored whether a combination mixture of TMZ and non-steroidal anti-inflammatory drugs …